Journal
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Volume 24, Issue 2, Pages 282-287Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2017.10.029
Keywords
Autologous transplantation; Mantle cell lymphoma; Total body irradiation; BEAM
Categories
Funding
- NCI NIH HHS [K23 CA154874] Funding Source: Medline
Ask authors/readers for more resources
Autologous stem cell transplant (ASCT) consolidation has become a standard approach for patients with mantle cell lymphoma (MCL), yet there is little consensus on the role of total body irradiation (TBI) as part of high dose transplantation conditioning. We analyzed 75 consecutive patients with MCL who underwent ASCT at our institution between 2001 and 2011 with either TBI-based (n = 43) or carmustine, etoposide, cytarabine, melphalan (BEAM; n = 32) high-dose conditioning. Most patients (97%) had chemosensitive disease and underwent transplantation in first remission (89%). On univariate analysis, TBI conditioning was associated with a trend toward improved PFS (hazard ratio [HR],.53; 95% confidence interval [CI],.28-1.00; P = .052) and similar OS (HR,.59; 95% CI,.26-135; P = .21), with a median follow-up of 63 years in the TBI group and 6.6 years in the BEAM group. The 5-year PFS was 66% in the TBI group versus 52% in the BEAM group; OS was 82% versus 68%, respectively. However, on multivariate analysis, TBI-based conditioning was not significantly associated with PFS (HR,.57; 95% CI.24-1.34; P = .20), after controlling for age, disease status at ASCT, and receipt of post transplantation rituximab maintenance. Likewise, early toxicity, nonrelapse mortality, and secondary malignancies were similar in the 2 groups. Our data suggest that both TBI and BEAM-based conditioning regimens remain viable conditioning options for patients with MCL undergoing ASCT. (C) 2017 American Society for Blood and Marrow Transplantation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available